Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis

Salgado, Caio Loureiro; Dias, Emmanoel Loss; Stringari, Lorenzzo Lyrio; Covre, Luciana Polaco; Dietze, Reynaldo; Pereira, Fausto Edmundo Lima; Guedes, Herbert Leonel de Matos; Rossi-Bergmann, Bartira; Gomes, Daniel Cláudio Oliveira

doi:10.1016/j.micinf.2019.02.005

Cited by 11 publications

(3 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No significant differences were observed in parasite burden, memory T cells, or IgG titers between groups vaccinated with the peptide with or without TLR2/3 agonists. These results are in accordance with a previous study demonstrating that a TLR2 agonist is unable to contribute to protection against L. infantum infection in an in vivo murine model [70]. Further investigation of alternative TLR agonists or combinations is warranted in the search for suitable vaccine adjuvants against L. infantum.…”

Section: Discussionsupporting

confidence: 92%

Enhancing Control of Leishmania infantum Infection: A Multi-Epitope Nanovaccine for Durable T-Cell Immunity

Hurtado-Morillas,

Martínez-Rodrigo,

Orden

et al. 2024

Animals

View full text Add to dashboard Cite

Canine leishmaniosis (CanL) is a growing health problem for which vaccination is a crucial tool for the control of disease. The successful development of an effective vaccine against this disease relies on eliciting a robust and enduring T-cell immune response involving the activation of CD4+ Th1 and CD8+ T-cells. This study aimed to evaluate the immunogenicity and prophylactic efficacy of a novel nanovaccine comprising a multi-epitope peptide, known as HisDTC, encapsulated in PLGA nanoparticles against Leishmania infantum infection in the murine model. The encapsulation strategy was designed to enhance antigen loading and sustain release, ensuring prolonged exposure to the immune system. Our results showed that mice immunized with PLGA-encapsulated HisDTC exhibited a significant reduction in the parasite load in the liver and spleen over both short and long-term duration. This reduction was associated with a cellular immune profile marked by elevated levels of pro-inflammatory cytokines, such as IFN-γ, and the generation of memory T cells. In conclusion, the current study establishes that PLGA-encapsulated HisDTC can promote effective and long-lasting T-cell responses against L. infantum in the murine model. These findings underscore the potential utility of multi-epitope vaccines, in conjunction with appropriate delivery systems, as an alternative strategy for CanL control.

show abstract

Section: Discussionsupporting

confidence: 92%

Enhancing Control of Leishmania infantum Infection: A Multi-Epitope Nanovaccine for Durable T-Cell Immunity

Hurtado-Morillas,

Martínez-Rodrigo,

Orden

et al. 2024

Animals

View full text Add to dashboard Cite

show abstract

“…Currently, there is not any approved vaccine against human leishmaniasis. 5 Nevertheless, several vaccine formulations are under evaluation in preclinical 6 , 7 , 8 and clinical trials (ClinicalTrials.gov Identifier: NCT02894008 and NCT03969134). The need to induce a Th1-type immune response in order to obtain protection was shown in Leishmania -murine models protection studies and in the immune profiles of self-healed individuals.…”

mentioning

confidence: 99%

Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis

Germanó

Lozano

Sánchez

et al. 2020

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response caused by them. OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)]. METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, sTLA was formulated with Poly (I:C) and their protective immune response was measured. FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis infection. MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice.

show abstract

“…Outra estratégia vacinal utilizando Pam3CSK4 é o de Salgado et al contra a leishmaniose visceral, a qual demonstrou um aumento na imunomodulação, porém não houve resposta imune protetora (Salgado et al, 2019). Até o momento, não há estudos abordando o uso de agonistas de TLR2 como adjuvantes em estratégias vacinais contra infecções fúngicas.…”

Section: Papel De Receptores De Reconhecimento Padrão Na Resposta Imunitária Do Hospedeiro Contra a Criptococoseunclassified

Efeito do agonista de TLR2-Pam3CSk4 em estratégia vacinal contra a infecção por Cryptococcus gattii

Campos¹

View full text Add to dashboard Cite

show abstract

Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis

Cited by 11 publications

References 68 publications

Enhancing Control of Leishmania infantum Infection: A Multi-Epitope Nanovaccine for Durable T-Cell Immunity

Enhancing Control of Leishmania infantum Infection: A Multi-Epitope Nanovaccine for Durable T-Cell Immunity

Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis

Efeito do agonista de TLR2-Pam3CSk4 em estratégia vacinal contra a infecção por Cryptococcus gattii

Contact Info

Product

Resources

About